Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects

NCT05244304 is registered in ClinicalTrials.gov with Belite Bio, Inc as lead sponsor.

NCT NCT05244304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05244304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
Lead sponsor
Belite Bio, Inc
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2022
Completion date
September 11, 2025
Enrollment
104 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

stargardt disease 1